009420.KS - HanAll Biopharma Co., Ltd.

KSE - KSE Delayed Price. Currency in KRW

HanAll Biopharma Co., Ltd.

Bongeunsaro114-gil 12
9th Floor
South Korea
82 2 2204 1753

Full Time Employees

Key Executives

Han-Soo LeeN/AN/A53
Mr. Seung-Kook Park Ph.D., M.B.A.N/AN/A54
Mr. Seong-Jin KimN/AN/A56
Sung-Soo JeonN/AN/A80
Jae-Hwan KimN/AN/A68
Amounts are as of December 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.


Hanall Biopharma Co., Ltd., a pharmaceutical company, focuses on drug delivery, biotherapeutics, and new small molecules discovery worldwide. Its products under development include HL036, a TNF-alpha receptor fragment for the treatment of inflammatory diseases caused by TNF-alpha, such as uveitis, dry eyes, and AMD; and HL161, an anti-Fc neonatal receptor mAb for the treatment of autoimmune diseases caused by IgG autoantibodies and immune complex mediated glomerular diseases. The company also develops HL040, a combination of atorvastatin and losartan that completed Phase III clinical trial to treat hyperlipidemia and hypertension; HL063B, a combination of telmisartan and chlorthalidone, which is in Phase III clinical trial for hypertension; and HL068, a combination of amlodipine and candesartan that is in Phase III clinical trial to treat hypertension. In addition, it develops HL172, a combination of metformin HCl and candesartan; HL009, an adenosylcobalamin liposomal gel that has completed Phase II clinical trial for atopic dermatisis; HL018, a metformin acetate for obesity/DM2; HL143, a Hanferon that is in Phase II clinical trial for the prevention of postoperative HCC recurrence; and HL032, an oral Vitatropin for growth hormone deficiency. Hanall Biopharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Corporate Governance

HanAll Biopharma Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.